8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 25, 2026·SEC
Celldex Therapeutics, Inc.(CLDX)Earnings, Financials & Key Ratios
CLDX•NASDAQ
Price updated Jun 19, 2026
AboutCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Show more
- Revenue$2M-78.6%
- EBITDA-$284M-48.0%
- Net Income-$259M-63.9%
- EPS (Diluted)-3.90-59.2%
- Gross Margin100%+104.5%
- EBITDA Margin-18934.67%-592.7%
- Operating Margin-19160%-589.5%
- Net Margin-17253.33%-667.2%
- ROE-40.62%-51.3%
CLDX Key Insights
Celldex Therapeutics, Inc. (CLDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 34.1% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 27.4% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLDX Price & Volume
Celldex Therapeutics, Inc. (CLDX) stock price & volume — 10-year historical chart
Loading chart...
CLDX Growth Metrics
Celldex Therapeutics, Inc. (CLDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-12.15%
5 Years-27.36%
3 Years-13.98%
TTM-89.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-58.15%
Return on Capital
10 Years-40.26%
5 Years-33.99%
3 Years-39.27%
Last Year-44.74%
CLDX Recent Earnings
Celldex Therapeutics, Inc. (CLDX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.18-2.9%
$1.15
Rev
$15,000-98.1%
$795,364
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$1.22-22.0%
$1.00
Rev
$100,000-92.4%
$1M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.01-14.8%
$0.88
Rev
—
$2M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.85+1.2%
$0.86
Rev
$730,000-38.3%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.18vs $1.15-2.9% | $15,000vs $795,364-98.1% |
| Q1 2026 | Feb 25, 2026 | $1.22vs $1.00-22.0% | $100,000vs $1M-92.4% |
| Q4 2025 | Nov 10, 2025 | $1.01vs $0.88-14.8% | —vs $2M |
| Q3 2025 | Aug 7, 2025 | $0.85vs $0.86+1.2% | $730,000vs $1M-38.3% |
Based on last 12 quarters of dataView full earnings history →
CLDX Peer Comparison
Celldex Therapeutics, Inc. (CLDX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare CLDX vs Peers
Celldex Therapeutics, Inc. (CLDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLDX Income Statement
Celldex Therapeutics, Inc. (CLDX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 12.74M | 9.54M | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M | 820K |
Revenue Growth % | 87.78% | -25.15% | -62.54% | 107.61% | -37.3% | -49.32% | 192.02% | 1.99% | -78.63% | -89.15% |
Cost of Goods Sold | 96.17M | 66.45M | 42.67M | 42.53M | 53.31M | 82.26M | 118.01M | 163.55M | 0 | 854K |
COGS % of Revenue | 754.7% | 696.68% | 1194.29% | 573.39% | 1146.23% | 3489.94% | 1714.53% | 2329.77% | - | - |
Gross Profit | -83.43M▲ 0% | -56.91M▲ 31.8% | -39.1M▲ 31.3% | -35.12M▲ 10.2% | -48.66M▼ 38.6% | -79.9M▼ 64.2% | -111.13M▼ 39.1% | -156.53M▼ 40.9% | 1.5M▲ 101.0% | -34K▲ 0% |
Gross Margin % | -654.7% | -596.68% | -1094.29% | -473.39% | -1046.23% | -3389.94% | -1614.53% | -2229.77% | 100% | -4.15% |
Gross Profit Growth % | 12.4% | 31.78% | 31.3% | 10.19% | -38.57% | -64.2% | -39.08% | -40.86% | 100.96% | - |
Operating Expenses | 38.1M | 99.53M | 15.93M | 28.24M | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M | 309.06M |
OpEx % of Revenue | 298.98% | 1043.46% | 445.9% | 380.67% | 485.55% | 1499.07% | 630.74% | 549.12% | 19260% | - |
Selling, General & Admin | 25M | 19.27M | 15.43M | 14.46M | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M | 44.43M |
SG&A % of Revenue | 196.21% | 202.02% | 431.74% | 194.88% | 440.51% | 1153.8% | 449.14% | 549.12% | 2920% | - |
Research & Development | 96.17M | 66.45M | 42.67M | 40.53M | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M | 265.49M |
R&D % of Revenue | 754.7% | 696.68% | 1194.29% | 546.43% | 1221.48% | 3489.94% | 1714.53% | 2329.77% | 16340% | - |
Other Operating Expenses | -83.08M | 13.81M | -42.17M | -26.75M | -54.72M | -74.12M | -105.51M | -163.55M | 0 | -854K |
Operating Income | -121.53M▲ 0% | -156.44M▼ 28.7% | -55.03M▲ 64.8% | -63.35M▼ 15.1% | -71.24M▼ 12.5% | -115.23M▼ 61.7% | -154.54M▼ 34.1% | -195.08M▼ 26.2% | -287.4M▼ 47.3% | -309.1M▲ 0% |
Operating Margin % | -953.68% | -1640.13% | -1540.19% | -854.06% | -1531.78% | -4889.01% | -2245.27% | -2778.89% | -19160% | -37694.63% |
Operating Income Growth % | 8.57% | -28.73% | 64.82% | -15.12% | -12.45% | -61.75% | -34.11% | -26.23% | -47.33% | - |
EBITDA | -116.22M | -152.63M | -50.17M | -59.42M | -68.17M | -112.34M | -151.53M | -191.9M | -284.02M | -305.73M |
EBITDA Margin % | -912.01% | -1600.28% | -1404.23% | -801.09% | -1465.81% | -4766.14% | -2201.57% | -2733.63% | -18934.67% | -37284.02% |
EBITDA Growth % | 9.79% | -31.34% | 67.13% | -18.44% | -14.72% | -64.78% | -34.89% | -26.64% | -48% | -42.9% |
D&A (Non-Cash Add-back) | 5.31M | 3.8M | 4.86M | 3.93M | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M | 3.37M |
EBIT | -109.33M | -76.4M | -54.52M | -49.57M | -69.15M | -107.1M | -142.04M | -195.08M | -258.8M | -303.27M |
Net Interest Income | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.61M | 25.42M |
Interest Income | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.61M | 25.42M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 4.21M | 4.49M | 4.15M | 2.41M | 505K | 2.91M | 13.11M | 37.22M | 28.6M | 25.41M |
Pretax Income | -117.31M▲ 0% | -151.95M▼ 29.5% | -50.88M▲ 66.5% | -60.95M▼ 19.8% | -70.74M▼ 16.1% | -112.33M▼ 58.8% | -141.43M▼ 25.9% | -157.86M▼ 11.6% | -258.8M▼ 63.9% | -283.69M▲ 0% |
Pretax Margin % | -920.61% | -1593.09% | -1423.96% | -821.61% | -1520.92% | -4765.59% | -2054.76% | -2248.76% | -17253.33% | -34596.22% |
Income Tax | -24.28M | -765K | 0 | -1.17M | -227K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 20.7% | 0.5% | 0% | 1.91% | 0.32% | 0% | 0% | 0% | 0% | 0% |
Net Income | -93.03M▲ 0% | -151.18M▼ 62.5% | -50.88M▲ 66.3% | -59.78M▼ 17.5% | -70.51M▼ 18.0% | -112.33M▼ 59.3% | -141.43M▼ 25.9% | -157.86M▼ 11.6% | -258.8M▼ 63.9% | -283.69M▲ 0% |
Net Margin % | -730.06% | -1585.07% | -1423.96% | -805.88% | -1516.04% | -4765.59% | -2054.76% | -2248.76% | -17253.33% | -34596.22% |
Net Income Growth % | 27.62% | -62.51% | 66.35% | -17.5% | -17.95% | -59.3% | -25.91% | -11.62% | -63.94% | -58.62% |
Net Income (Continuing) | -93.03M | -151.18M | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M | -157.86M | -258.8M | -283.69M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -10.86▲ 0% | -14.48▼ 33.3% | -3.51▲ 75.8% | -2.02▲ 42.5% | -1.64▲ 18.8% | -2.40▼ 46.3% | -2.92▼ 21.7% | -2.45▲ 16.1% | -3.90▼ 59.2% | -4.26▲ 0% |
EPS Growth % | 42.81% | -33.33% | 75.76% | 42.45% | 18.81% | -46.34% | -21.67% | 16.1% | -59.18% | -58.15% |
EPS (Basic) | -10.86 | -14.48 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 | - |
Diluted Shares Outstanding | 8.57M | 10.44M | 14.51M | 29.64M | 42.87M | 46.89M | 48.45M | 64.39M | 66.5M | 66.57M |
Basic Shares Outstanding | 8.57M | 10.44M | 14.51M | 29.64M | 42.87M | 46.89M | 48.45M | 64.39M | 66.5M | 66.57M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLDX Balance Sheet
Celldex Therapeutics, Inc. (CLDX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 144.76M | 99.08M | 66.7M | 197.84M | 410.84M | 317.69M | 431.69M | 747.16M | 534.66M | 459.22M |
Cash & Short-Term Investments | 139.43M | 94.02M | 64.18M | 194.42M | 408.25M | 304.95M | 421.7M | 725.28M | 518.57M | 451.46M |
Cash Only | 40.29M | 24.31M | 11.23M | 43.84M | 39.14M | 29.43M | 34.81M | 28.36M | 28.87M | 35.73M |
Short-Term Investments | 99.14M | 69.71M | 52.95M | 150.59M | 369.11M | 275.52M | 386.88M | 696.92M | 489.7M | 415.73M |
Accounts Receivable | 1.88M | 3.16M | 1.22M | 1.8M | 172K | 347K | 4.53M | 700K | 2.02M | 230K |
Days Sales Outstanding | 53.85 | 121 | 124.12 | 88.67 | 13.5 | 53.74 | 240.12 | 36.4 | 490.32 | 269.86 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 5.47M | 21.18M | 14.08M | 7.53M |
Total Non-Current Assets | 170.87M | 56.73M | 56.23M | 37.99M | 33.81M | 35.04M | 33.93M | 45.18M | 48.32M | 52.03M |
Property, Plant & Equipment | 10.37M | 6.11M | 7.5M | 7.26M | 6.52M | 7.75M | 6.64M | 8.24M | 7.77M | 9.41M |
Fixed Asset Turnover | 1.23x | 1.56x | 0.48x | 1.02x | 0.71x | 0.30x | 1.04x | 0.85x | 0.19x | 0.10x |
Goodwill | 90.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 67.59M | 50.62M | 48.69M | 30.69M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3.73M | 3.73M | 41K | 41K | 104K | 104K | 107K | 9.75M | 13.36M | 15.43M |
Total Assets | 315.62M▲ 0% | 155.81M▼ 50.6% | 122.93M▼ 21.1% | 235.84M▲ 91.8% | 444.65M▲ 88.5% | 352.74M▼ 20.7% | 465.63M▲ 32.0% | 792.34M▲ 70.2% | 582.98M▼ 26.4% | 511.25M▲ 0% |
Asset Turnover | 0.04x | 0.06x | 0.03x | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
Asset Growth % | -17.67% | -50.63% | -21.1% | 91.84% | 88.54% | -20.67% | 32% | 70.17% | -26.42% | -96.63% |
Total Current Liabilities | 27.74M | 12.6M | 11.64M | 14.21M | 16.53M | 18.61M | 31.13M | 39.5M | 50.99M | 51.47M |
Accounts Payable | 1.72M | 1.07M | 1.17M | 1.05M | 1.23M | 3.34M | 3.49M | 3.27M | 1.18M | 10.36M |
Days Payables Outstanding | 6.51 | 5.87 | 10.04 | 8.99 | 8.41 | 14.82 | 10.81 | 7.29 | - | 1.91K |
Short-Term Debt | 6.57M | 4.53M | 1.94M | 0 | 0 | 0 | 0 | 0 | 1.55M | 1.47M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 2.01M | 3.37M | 1.55M | 990K | 3.99M | 942K | 48.26M | 39.65M |
Current Ratio | 5.22x | 7.86x | 5.73x | 13.93x | 24.86x | 17.07x | 13.87x | 18.91x | 10.49x | 8.92x |
Quick Ratio | 5.22x | 7.86x | 5.73x | 13.93x | 24.86x | 17.07x | 13.87x | 18.91x | 10.49x | 8.92x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.64K |
Total Non-Current Liabilities | 51.52M | 19.15M | 17.26M | 12.28M | 8.65M | 7.92M | 5.33M | 5.83M | 4.83M | 3.56M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 443K |
Capital Lease Obligations | 0 | 0 | 1.71M | 2.15M | 1.3M | 2.59M | 928K | 2.36M | 784K | 3.35M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 51.52M | 19.15M | 15.55M | 10.12M | 7.35M | 5.33M | 4.4M | 3.47M | 4.04M | 3.11M |
Total Liabilities | 79.25M | 31.75M | 28.91M | 26.48M | 25.18M | 26.53M | 36.46M | 45.34M | 55.82M | 55.03M |
Total Debt | 6.57M | 4.53M | 3.66M | 3.48M | 3.04M | 4.03M | 2.54M | 3.81M | 2.34M | 1.91M |
Net Debt | -33.72M | -19.78M | -7.58M | -40.35M | -36.1M | -25.4M | -32.27M | -24.54M | -26.54M | -33.82M |
Debt / Equity | 0.03x | 0.04x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.11x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 236.37M▲ 0% | 124.06M▼ 47.5% | 94.03M▼ 24.2% | 209.36M▲ 122.7% | 419.48M▲ 100.4% | 326.2M▼ 22.2% | 429.17M▲ 31.6% | 747M▲ 74.1% | 527.16M▼ 29.4% | 456.23M▲ 0% |
Equity Growth % | -10.95% | -47.51% | -24.21% | 122.66% | 100.36% | -22.24% | 31.57% | 74.06% | -29.43% | -107.84% |
Book Value per Share | 27.58 | 11.88 | 6.48 | 7.06 | 9.78 | 6.96 | 8.86 | 11.60 | 7.93 | 6.85 |
Total Shareholders' Equity | 236.37M | 124.06M | 94.03M | 209.36M | 419.48M | 326.2M | 429.17M | 747M | 527.16M | 456.23M |
Common Stock | 139K | 12K | 17K | 40K | 47K | 47K | 56K | 66K | 67K | 67K |
Retained Earnings | -812.52M | -962.44M | -1.01B | -1.07B | -1.14B | -1.26B | -1.4B | -1.56B | -1.81B | -1.89B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 2.56M | 2.58M | 2.62M | 2.59M | 1.89M | 1.26M | 3.31M | 3.31M | 3.63M | 2.52M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLDX Cash Flow Statement
Celldex Therapeutics, Inc. (CLDX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -99.93M | -75.23M | -46.41M | -40.4M | -60.91M | -103.73M | -107.29M | -157.78M | -210.94M | -222.16M |
Operating CF Margin % | -784.2% | -788.79% | -1299.05% | -544.68% | -1309.59% | -4401.02% | -1558.78% | -2247.55% | -14063% | - |
Operating CF Growth % | 11.59% | 24.71% | 38.31% | 12.95% | -50.75% | -70.31% | -3.43% | -47.06% | -33.7% | -155.44% |
Net Income | -93.03M | -151.18M | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M | -157.86M | -258.76M | -283.69M |
Depreciation & Amortization | 5.31M | 3.8M | 4.86M | 3.93M | 3.07M | 1.4M | 3.01M | 3.18M | -2.48M | 5.81M |
Stock-Based Compensation | 12.31M | 8.08M | 4.55M | 3.92M | 8.95M | 0 | 23.89M | 34.24M | 36.22M | 35.42M |
Deferred Taxes | -24.28M | -765K | 671K | -1.17M | -227K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 11.96M | 80.2M | -1.29M | 13M | -1.14M | 11.09M | -6.22M | -15.73M | 12K | -6.65M |
Working Capital Changes | -12.21M | -15.37M | -4.32M | -299K | -1.05M | -3.9M | 13.46M | -21.6M | 14.06M | 26.9M |
Change in Receivables | -96K | -777K | -777K | -787K | 1.57M | -175K | -2.28M | 1.93M | -1.31M | 834K |
Change in Inventory | -3.57M | 1.78M | 13.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -8.74M | -13.11M | -13.11M | 1.64M | 3.65M | 3.12M | 9.38M | 11.63M | 11.03M | 19.46M |
Cash from Investing | 46.47M | 29.82M | 17.08M | -98.22M | -216.16M | 89.94M | -105.78M | -290.13M | 209.07M | 238.24M |
Capital Expenditures | -1.79M | -813K | -731K | -1.55M | -1.25M | -1.83M | -1.82M | -1.92M | -2.71M | -3.8M |
CapEx % of Revenue | 14.03% | 8.52% | 20.46% | 20.92% | 26.85% | 77.56% | 26.41% | 27.34% | 180.93% | 463.41% |
Acquisitions | 1.79M | 342K | 20K | 55K | 27K | 69K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -288K |
Cash from Financing | 51.29M | 29.44M | 16.26M | 171.23M | 272.37M | 4.08M | 218.46M | 441.45M | 2.39M | 2.51M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 51.02M | 29.02M | 16.25M | 170.79M | 269.89M | 4.08M | 216.22M | 432.3M | 2.39M | 2.51M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 265K | 419K | 9K | 434K | 2.48M | 0 | 2.24M | 9.15M | 0 | 0 |
Net Change in Cash | -2.17M▲ 0% | -15.98M▼ 635.3% | -13.08M▲ 18.1% | 32.6M▲ 349.3% | -4.69M▼ 114.4% | -9.71M▼ 107.0% | 5.38M▲ 155.4% | -6.46M▼ 219.9% | 515K▲ 108.0% | 18.59M▲ 0% |
Free Cash Flow | -101.72M▲ 0% | -76.05M▲ 25.2% | -47.15M▲ 38.0% | -41.96M▲ 11.0% | -62.16M▼ 48.2% | -105.56M▼ 69.8% | -109.11M▼ 3.4% | -159.7M▼ 46.4% | -213.66M▼ 33.8% | -225.96M▲ 0% |
FCF Margin % | -798.23% | -797.32% | -1319.51% | -565.6% | -1336.44% | -4478.57% | -1585.2% | -2274.89% | -14243.93% | -27556.22% |
FCF Growth % | 12.15% | 25.24% | 38% | 11.01% | -48.15% | -69.83% | -3.36% | -46.36% | -33.79% | -31.23% |
FCF per Share | -11.87 | -7.28 | -3.25 | -1.42 | -1.45 | -2.25 | -2.25 | -2.48 | -3.21 | -3.39 |
FCF Conversion (FCF/Net Income) | 1.07x | 0.50x | 0.91x | 0.68x | 0.86x | 0.92x | 0.76x | 1.00x | 0.82x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLDX Key Ratios
Celldex Therapeutics, Inc. (CLDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -37.08% | -83.89% | -46.66% | -39.41% | -22.43% | -30.13% | -37.45% | -26.84% | -40.62% | -50.72% |
Return on Invested Capital (ROIC) | -42.83% | -76.45% | -43.28% | -37.2% | -19.35% | -25.26% | -33.23% | -26.14% | -35.25% | -43.67% |
Gross Margin | -654.7% | -596.68% | -1094.29% | -473.39% | -1046.23% | -3389.94% | -1614.53% | -2229.77% | 100% | -4.15% |
Net Margin | -730.06% | -1585.07% | -1423.96% | -805.88% | -1516.04% | -4765.59% | -2054.76% | -2248.76% | -17253.33% | -34596.22% |
Debt / Equity | 0.03x | 0.04x | 0.04x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
FCF Conversion | 1.07x | 0.50x | 0.91x | 0.68x | 0.86x | 0.92x | 0.76x | 1.00x | 0.82x | 0.80x |
Revenue Growth | 87.78% | -25.15% | -62.54% | 107.61% | -37.3% | -49.32% | 192.02% | 1.99% | -78.63% | -89.15% |
Related:CLDX Dividend History·CLDX Revenue History·CLDX Price History·CLDX P/E History·CLDX Financial Ratios·CLDX Institutional Holders
CLDX SEC Filings & Documents
Celldex Therapeutics, Inc. (CLDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLDX Frequently Asked Questions
Celldex Therapeutics, Inc. (CLDX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Celldex Therapeutics, Inc. (CLDX) reported $0.8M in revenue for fiscal year 2025. This represents a 25% decrease from $1.1M in 1996.
Celldex Therapeutics, Inc. (CLDX) saw revenue decline by 78.6% over the past year.
Celldex Therapeutics, Inc. (CLDX) reported a net loss of $283.7M for fiscal year 2025.
Dividend & Returns
Celldex Therapeutics, Inc. (CLDX) has a return on equity (ROE) of -40.6%. Negative ROE indicates the company is unprofitable.
Celldex Therapeutics, Inc. (CLDX) had negative free cash flow of $226.0M in fiscal year 2025, likely due to heavy capital investments.